Merck to acquire Cidara Therapeutics for $9.2 billion

Diversifying its portfolio to include late-phase antiviral agent

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

Samsung Epis launches new biotech subsidiary Epis NexLab

The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy

Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3

Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion

Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr

Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal